ReviewPsychopharmacology2019
Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.
Review in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.Psychiatric services (Washington, D.C.) · 2021Pooled it
- Endocannabinoids inhibit contextual fear memory generalization via hippocampal GABAergic synaptic transmission.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer's disease through potentiating the function of extrasynaptic glycine receptors.Molecular psychiatry · 2025Article
- Identifying molecular signatures of post-traumatic stress disorder vulnerability and progression in a longitudinal study: a study protocol.Frontiers in psychiatry · 2025Article
- Brain region specific regulation of anandamide (down) and sphingosine-1-phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress.Pflugers Archiv : European journal of physiology · 2024Article
- Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders.Neuronal signaling · 2023Review
- The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol.Current neuropharmacology · 2023Review
- FAAH polymorphism (rs324420) modulates extinction recall in healthy humans: an fMRI study.European archives of psychiatry and clinical neuroscience · 2022Article
- Phosphatidylethanolamine Deficiency and Triglyceride Overload in Perilesional Cortex Contribute to Non-Goal-Directed Hyperactivity after Traumatic Brain Injury in Mice.Biomedicines · 2022Article
- Endocannabinoid metabolism inhibition has no effect on spontaneous fear recovery or extinction resistance in Lister hooded rats.Frontiers in pharmacology · 2022Article
- Understanding the dynamic and destiny of memories.Neuroscience and biobehavioral reviews · 2021Review
- Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice.Journal of translational medicine · 2021Article
- Cannabidiol and Sertraline Regulate Behavioral and Brain Gene Expression Alterations in an Animal Model of PTSD.Frontiers in pharmacology · 2021Article
- From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?Frontiers in psychiatry · 2021Review
- The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health.Current neuropharmacology · 2021Review
- Genes associated with cognitive performance in the Morris water maze: an RNA-seq study.Scientific reports · 2020Article
- Meet Your Stress Management Professionals: The Endocannabinoids.Trends in molecular medicine · 2020Review
- Low brain endocannabinoids associated with persistent non-goal directed nighttime hyperactivity after traumatic brain injury in mice.Scientific reports · 2020Article
- The role of prelimbic and anterior cingulate cortices in fear memory reconsolidation and persistence depends on the memory age.Learning & memory (Cold Spring Harbor, N.Y.) · 2020Article
- Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective.Frontiers in neurology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
rationaleAversive learning and memory are essential to cope with dangerous and stressful stimuli present in an ever-changing environment. When this process is dysfunctional, however, it is associated with posttraumatic stress disorder (PTSD). The endocannabinoid (eCB) system has been implicated in synaptic plasticity associated with physiological and pathological aversive learning and memory. OBJECTIVE AND
methodsThe objective of this study was to review and discuss evidence on how and where in the brain genetic or pharmacological interventions targeting the eCB system would attenuate aversive/traumatic memories through extinction facilitation in laboratory animals and humans. The effect size of the experimental intervention under investigation was also calculated.
resultsCurrently available data indicate that direct or indirect activation of cannabinoid type-1 (CB1) receptor facilitates the extinction of aversive/traumatic memories. Activating CB1 receptors around the formation of aversive/traumatic memories or their reminders can potentiate their subsequent extinction. In most cases, the effect size has been large (Cohen's d ≥ 1.0). The brain areas responsible for the abovementioned effects include the medial prefrontal cortex, amygdala, and/or hippocampus. The potential role of cannabinoid type-2 (CB2) receptors in extinction learning is now under investigation.
conclusionDrugs augmenting the brain eCB activity can temper the impact of aversive/traumatic experiences by diverse mechanisms depending on the moment of their administration. Considering the pivotal role the extinction process plays in PTSD, the therapeutic potential of these drugs is evident. The sparse number of clinical trials testing these compounds in stress-related disorders is a gap in the literature that needs to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.